In this week’s PharmaSignal Weekly Brief – Global Pharma Roundup, we see a flurry of M&A activity, key regulatory approvals, and significant pipeline developments. Meanwhile, the global pharma landscape is also being shaped by important market, pricing, and policy signals. M&A and Strategic Deals Johnson & Johnson’s acquisition of Halda Therapeutics for $3.05 billion marks a significant expansion in their oncology portfolio. Read more → Novo Nordisk’s $5.2 billion acquisition of Akero Therapeutics is set to boost their metabolic disease treatment offerings. Read more → Regulatory and Approvals Arrowhead’s Redemplo received FDA approval, marking a significant advancement in gene therapy.…